The Innovative Medicines Initiative (IMI) organised a series of online live sessions on its impact. During the events, key actors explored the challenges faced and demonstrated how IMI contributed towards overcoming them. The IMI is a partnership between the European Union and the European pharmaceutical industry. It facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.
The Initiative has decided to showcase IMI’s impact in specific areas, starting with three topics: diabetes, dementia and the relatively new field of data management. They analysed the challenges and showed how IMI-funded projects helped to move the needle. IMI has over 20 projects in the of dementia and neurodegeneration, accounting for around 10 % of IMI’s budget. Most focus on Alzheimer’s disease, the most prevalent cause of dementia.
Outline of the event and presentations
The challenge, the vision and the value
Luc Truyen, Global Head- Development and External Affairs-Neuroscience, Janssen Pharmaceutical Companies of Johnson & Johnson Presentation
Helen Rochford-Brennan, Member and past Chair, Alzheimer Europe European Working Group of People with Dementia
How IMI projects have addressed the challenge & ‘moved the needle’ , Solutions from IMI projects
Carlos Diaz, CEO, SYNAPSE Research Management Partners. S.L, NEURONET Presentation
Rachel Steeg, Fraunhofer UK Research Ltd, EBISC2 Presentation
Gill Farrar, Global Medical Leader, GE Healthcare Medical Affairs, AMYPAD Presentation
Professor Olivier Blin, Head of the Clinical Pharmacology & Pharmacovigilance Department, Aix-Marseille University, Member of IMI Scientific Committee
Have a look at their events page and watch the presentations on diabetes and data.